Investor Presentaiton
In sum, we believe Coloplast can continue to deliver stable shareholder
returns through ...
Organic growth and EBIT margin development
Highlights
28%
12%
8%
•
7%
07/08
09/10
11/12
13/14
15/16
17/18
19/20
21/22 YTD
22/23
Organic growth
EBIT Margin²
10%
FCF and ROIC development
19%
9%
8%
07/08
09/10
11/12
13/14
15/16
17/18
19/20
21/22 YTD
22/23
FCF to sales¹
ROIC after tax²
1. FCF adjusted for Mesh payments in 2013/14, 2014/15, 2015/16, 2016/17, 2017/18, 2018/19, 2020/21, 2021/22, YTD 2022/23 and acquisitions in 2016/17, 2017/18 and 2020/21 and 2021/22. YTD
2022/23 adjusted for payment related to the formal resolution of the US Veteran Affairs matter Adjustment for Mesh payments includes DKK 500m insurance coverage in 2013/14 and 2014/15 combined. 2
Before special items. Special items include: 2013/14 DKK 1bn net provision; 2014/15 DKK 3bn provision; 2015/16 DKK 0.75bn provision; 2018/19 DKK 0.4bn provision; 2020/21 DKK 0.2bn provision; 2021/22
DKK 471m, Mesh litigation provisions and Atos Medical integration costs; YTD 2022/23 DKK 33m, Atos Medical integration costs
.
Stable market trends in our
Chronic Care business
Innovative product portfolio and new product
launches
Strong Coloplast Care retention program
and innovative DtC activities
Increased focus on growing the business
outside Europe
Additional improvements in manufacturing
by leveraging global operations footprint
European leverage will provide funds for further
investments in sales initiatives
Resulting in strong free cash flow generation
and high return on invested capital
ROIC FY 21/22 and H1 22/23 impacted by the
recent acquisition of Atos Medical
44
ColoplastView entire presentation